Our latest articles
Spotlight – Nash in 2023 and beyond
The mid-stage Nash pipeline plays host to mechanisms both evidence-backed and unproven, with plenty of data on the horizon.
Biogen hopes to bridge the gap with $7.3bn Reata buy
Biogen’s acquisition of rare neurological disease player Reata provides a much needed near-term sales lift, but at a price.
Spotlight – scratching the surface of the urticaria pipeline
Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.
Home Bioscience eyes fresh funds
With a focus on France and Germany, the company builder is also closing in on its final two targets.
AAIC 2023 – Lilly downplays tau testing needs
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
Sanofi goes back to Scribe
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
Argenx surges after hit in nerve disorder
The Belgian group is riding high as investors look for future successes in other inflammatory diseases.
Bridgebio finally gets its cardiomyopathy win
A convincing hit puts approval, and potentially partnerships, on the table.